ライフサイエンスコーパス: evidence-based treatment

1 e results are highly desirable to facilitate evidence-based treatment.

2 the need for randomized trials to allow for evidence-based treatment.

3 rs, yet just 1 in 10 of these women receives evidence-based treatment.

4 ween identification and implementation of an evidence-based treatment.

5 ronic form of AN for which there is no known evidence-based treatment.

6 ed using the known natural history of ROP vs evidence-based treatment.

7 ovascular disease, and failure to use proper evidence based treatments.

8 in units that systematically use these other evidence-based treatments.

9 Childhood mood disorders lack sufficient evidence-based treatments.

10 ethodological quality, and identification of evidence-based treatments.

11 ith only 33% (21 of 63) and 19% (6 of 32) on evidence-based treatments.

12 d a starting point for further research into evidence-based treatments.

13 a risk for poor quality of life (QOL) and no evidence-based treatments.

14 timulant co-use is a common problem with few evidence-based treatments.

15 increased reach of, and equity of access to, evidence-based treatments.

16 hown by the limited success rates across all evidence-based treatments.

17 ng consensus recommendations that underscore evidence-based treatments.

18 cide risk for veterans differs by receipt of evidence-based treatments.

19 matic treatments are also needed to identify evidence-based treatments.

20 impede rural veterans from engaging in these evidence-based treatments.

21 to improve quality by quantifying the use of evidence-based treatments.

22 ldren and adolescents for which there are no evidence-based treatments.

23 fit from further research and development of evidence-based treatments.

24 o be offered in primary care alongside other evidenced based treatments.

25 symptoms, while psychotherapy is an emerging evidence based treatment across FND subtypes.

26 coagulopathy, have been characterized and an evidence-based treatment algorithm is available.

27 med with each compound is used to propose an evidence-based treatment algorithm.

28 Clear, focused, and evidence-based treatment algorithms are needed to suppor

29 s like ARIA and EPOS provide clinicians with evidence-based treatment algorithms for allergic rhiniti

30 lt PAH have been used to treat children, but evidence-based treatment algorithms for children are lac

31 ilonidal disease and its outcomes to develop evidence-based treatment algorithms.

32 py is needed to ensure culturally competent, evidence-based treatment aligned with the highest standa

33 linicians about health risks of cannabis and evidence-based treatment alternatives.

34 testing (AST) technologies that will enable evidence-based treatment and promote antimicrobial stewa

35 The underuse of evidence-based treatments and delayed reperfusion among

36 ogy inpatient service more commonly received evidence-based treatments and had a lower risk of mortal

37 Clinical trials to support evidence-based treatments and the development of disease

38 ology, outcomes, causes and pathophysiology, evidence-based treatment, and a call for action.

39 tention of drug users in centres offering no evidence-based treatment, and imprisonment for possessio

40 siology of smoke inhalation injury, the best evidence-based treatments, and challenges and future dir

41 t, seek consensus on diagnostic criteria and evidence-based treatments, and describe the pathophysiol

42 al in-person engagement session, delivery of evidence-based treatments, and regular follow-up by mast

43 aphasia after stroke, providing an effective evidence-based treatment approach in this population.

44 Prompt recognition and an evidence-based treatment approach is the key to successf

45 population and the lack of standardized and evidence-based treatment approaches make treatment a dif

46 Few evidence-based treatments are available for Gulf War ill

47 Evidence-based treatments are available for patients wit

48 Evidence-based treatments are available for the manageme

49 No evidence-based treatments are available to reduce this r

50 Few evidence-based treatments are currently available for BE

51 ive understanding of TTS pathophysiology and evidence-based treatments are lacking, and specific and

52 valent and impairing among young people, and evidence-based treatments are limited.

53 iscrepancy, Martin Raw, Honorary Lecturer in evidence-based treatment at Guys, Kings and St Thomas' S

54 ferred by criminal justice agencies received evidence-based treatment at lower rates than women refer

55 ally need to focus on improving the rates of evidence-based treatment at sites with high proportions

56 inesterase inhibition is the only high-level evidence-based treatment available, but other pharmacolo

57 nts and for development and testing of novel evidence-based treatments, both trauma-focused and non-t

58 There is no evidence-based treatment, but various systemic immunomod

59 These findings may help guide evidence-based treatment choices for TRD.

60 Evidence-based treatment decisions for advanced gastroen

61 onsortium convened a public workshop titled "Evidence-Based Treatment Decisions in Transplantation: T

62 croorganisms has the potential to facilitate evidence-based treatment decisions, antimicrobial select

63 nderrepresented in clinical trials, limiting evidence-based treatment decisions.

64 anisms that underlie relapse is critical for evidence-based treatment development.

65 allenges with scaling up multiple structured evidence-based treatments (EBTs), a transdiagnostic trea

66 sustained implementation of and adherence to evidence-based treatments, especially in resource-limite

67 Evidence-based treatment established for these condition

68 recognized and infrequently treated, and few evidence-based treatments exist.

69 ogy and manage both vascularized PEDs, where evidence-based treatment exists, and nonvascularized PED

70 The delayed and modest uptake of evidence-based treatments following cardiovascular clini

71 This is the first evidence-based treatment for a skeletal muscle channelop

72 Cognitive behavioral therapy (CBT) is an evidence-based treatment for alcohol use, yet patient ac

73 iews of extending behavioural activation, an evidence-based treatment for depression, to the negative

74 However, there is still no firmly evidence-based treatment for heart failure with preserve

75 As the first evidence-based treatment for HFpEF, in the EMPEROR-Prese

76 icacy trial to establish BRIGHT as the first evidence-based treatment for HNC survivors with BID.

77 There is an urgent need increase access to evidence-based treatment for insomnia in cancer centers

78 cognitive behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been teste

79 Although urban-rural disparities in evidence-based treatment for myocardial infarction in Ch

80 Mexiletine is the first evidence-based treatment for nondystrophic myotonias.

81 y or fibrinolysis is the currently available evidence-based treatment for obstructive mechanical valv

82 rsening overdose crisis, improving access to evidence-based treatment for opioid use disorder (OUD) r

83 Methadone treatment is the most effective evidence-based treatment for opioid use disorder (OUD),

84 Medication is the only evidence-based treatment for opioid use disorder; howeve

85 targets problem-solving impairment and is an evidence-based treatment for other conditions.

86 est that to increase access to compassionate evidence-based treatment for OUD, clinicians need ongoin

87 Inebilizumab has potential application as an evidence-based treatment for patients with NMOSD.

88 tion across countries and will contribute to evidence-based treatment for patients with threatened pr

89 Cognitive processing therapy (CPT), an evidence-based treatment for posttraumatic stress disord

90 potential mechanism for expanding access to evidence-based treatment for pregnant women in the US.

91 h the exception of azithromycin, there is no evidence-based treatment for primary ciliary dyskinesia;

92 e behavioral therapy (CBT) is an established evidence-based treatment for SAD, but its availability i

93 Bright light therapy is an evidence-based treatment for seasonal depression, but th

94 titive TMS has developed into an established evidence-based treatment for various neuropsychiatric di

95 eneficial effects are additional to those of evidence-based treatments for acute myocardial infarctio

96 he development of targeted interventions and evidence-based treatments for alcohol use among female i

97 Current evidence-based treatments for anorexia nervosa were deve

98 ably more deaths per year than would various evidence-based treatments for cardiovascular disease.

99 the breadth of target problems that current evidence-based treatments for child posttraumatic stress

100 tus and physicians' adherence with providing evidence-based treatments for coronary artery disease (C

101 d products, and undermine efforts to develop evidence-based treatments for COVID-19.

102 Although evidence-based treatments for depression in low-resource

103 Significant underuse of evidence-based treatments for depression persists in pri

104 arate and modular/integrated arrangements of evidence-based treatments for depression, anxiety, and c

105 zed controlled trials have produced separate evidence-based treatments for depression, anxiety, and c

106 sease risk, and the increased application of evidence-based treatments for established coronary heart

107 There is a conspicuous paucity of evidence-based treatments for FNS.

108 Evidence-based treatments for major depressive disorder

109 Evidence-based treatments for metastatic, human epiderma

110 Evidence-based treatments for metastatic, human epiderma

111 The promise of evidence-based treatments for morphea in the near future

112 with a primary care practitioner to deliver evidence-based treatments for OUD, major depression, and

113 , no randomized clinical trials have studied evidence-based treatments for OVC in low-resource settin

114 rmulate hypotheses for development of novel, evidence-based treatments for post-traumatic epilepsy by

115 ols, has the potential to increase access to evidence-based treatments for posttraumatic stress disor

116 Evidence-based treatments for posttraumatic stress disor

117 veterans who have poor adherence to existing evidence-based treatments for posttraumatic stress disor

118 Evidence-based treatments for posttraumatic stress disor

119 This article offers (a) an overview of evidence-based treatments for PTSD, (b) a description of

120 th chronic kidney disease, but there are few evidence-based treatments for reducing cardiovascular ev

121 Evidence-based treatments for suicide risk exist, but th

122 r depression by age 18 years yet few receive evidence-based treatments for their depression.

123 Despite demonstrated efficacy, evidence-based treatments for these conditions are often

124 To date there is a severe paucity of evidence-based treatments for these conditions.

125 There is currently a lack of evidence-based treatments for this highly complex syndro

126 Promote the further development of evidence-based treatments for tobacco cessation, includi

127 Integrating evidenced-based treatment for depression with evidenced-

128 is a need for comparative studies to provide evidence-based treatment guidance for biologic agents in

129 sialorrhea carries a significant burden, but evidence-based treatment guidance is incomplete, warrant

130 adverse cardiac outcome may facilitate more evidence-based treatment guidance.

131 Evidence-based treatment guidelines are not available fo

132 stent hypoparathyroidism, and use of uniform evidence-based treatment guidelines enables comparison o

133 studies are warranted in order to formulate evidence-based treatment guidelines for patients with ce

134 ctive data should support the development of evidence-based treatment guidelines for patients with Sy

135 RATIONALE: The development of evidence-based treatment guidelines for pediatric pulmon

136 Adherence to evidence-based treatment guidelines has been proposed as

137 Adherence to evidence-based treatment guidelines in rectal cancer is

138 inical judgment in situations not covered by evidence-based treatment guidelines.

139 , and current treatment practices lag behind evidence-based treatment guidelines.

140 n emphasis on meta-analyses and contemporary evidence-based treatment guidelines.

141 Evidence-based treatment has led to dramatic improvement

142 New evidence-based treatments have greatly expanded the medi

143 a promising way to build on the strengths of evidence-based treatments, improving their utility and e

144 expectancy of a patient strongly influences evidence-based treatment in acute myocardial infarction.

145 , partly because of high levels of empirical-evidence-based treatment in smear-negative patients.

146 ce 2020, with the increasing availability of evidence-based treatments in two main classes: antiviral

147 Evidence-based treatments include cognitive behavioural

148 Other evidence-based treatments include specific antidepressan

149 Although no level 1 evidence-based treatment is currently available for CRAO

150 has a population prevalence of about 1%, but evidence-based treatment is lacking.

151 g information about symptoms, diagnosis, and evidence-based treatments is a first step in helping pat

152 ant psychosocial problems, for which we have evidence-based treatments, many patients still do not re

153 M structured its review according to current evidence-based treatment modalities in HCC and prioritiz

154 hy can readily be diagnosed, enabling future evidence-based treatment of affected couples.

155 Clinical considerations for evidence-based treatment of borderline personality disor

156 ies, with the aim of supporting the safe and evidence-based treatment of end-stage T2D and judicious

157 Although hypertension is common in CKD and evidence-based treatment of hypertension has changed con

158 ve been achieved, however identification and evidence-based treatment of intellectual disabled offend

159 nical and biological questions and effective evidence-based treatment of patients with these inherite

160 Moreover, the integration of evidence-based treatments of adolescent substance abuse

161 pproach outperformed usual care and standard evidence-based treatments on multiple clinical outcome m

162 Robust evidence-based treatment options are lacking.

163 Efficacious evidence-based treatment options are needed for this pat

164 as Leigh syndrome and there are very limited evidence-based treatment options available.

165 rrent limitations to the reach and uptake of evidence-based treatment options for prediabetes.

166 Evidence-based treatment options include a range of psyc

167 testicular cancer, and scientifically driven evidence-based treatment options should improve quality

168 ition of frailty, furthering advancements in evidence-based treatment options, and identifying cost-e

169 disease is challenging because there are few evidence-based treatment options, and pulmonary vasodila

170 outcomes across these rare diseases with few evidence-based treatment options.

171 disease characterisation and availability of evidence-based treatment options.

172 were less likely than whites to receive many evidence-based treatments, particularly those that are c

173 e is variable, and there is low adherence to evidence-based treatment pathways.

174 es has the potential to enable comprehensive evidence-based treatment plans to be implemented quickly

175 acilitate the development of child-specific, evidence-based treatment plans.

176 burden regions, with direct implications for evidence-based treatment policy and vaccine rollout stra

177 arkers and care bundles - structured sets of evidence-based treatment practices - to improve the clin

178 pathophysiology, multifactorial aetiologies, evidenced-based treatments, prevention strategies and ma

179 There is no evidence-based treatment recommendation for individuals

180 allenging in view of the paucity of data and evidence-based treatment recommendations are missing.

181 As a result, evidence-based treatment recommendations are possible fo

182 Clinical trials have led to evidence-based treatment recommendations for advanced te

183 We provide evidence-based treatment recommendations using the GRADE

184 we review recent literature to guide current evidence-based treatment recommendations via illustrativ

185 When compared to evidence-based treatment recommendations, these changes

186 sistent and reflect the need for efficacious evidence-based treatment regimens.

187 ention to alter patient trajectories, though evidence based treatment remains lacking.

188 nt management, improved prognostication, and evidence-based treatment selection.

189 Evidence-based treatments should be available to these i

190 ly prevalent among young people, yet current evidence-based treatments show variable outcomes.

191 MFCLs are one evidence-based treatment shown to be effective in slowin

192 sing identified gaps is essential to develop evidence-based treatment strategies and enhance patient

193 T, underscoring the continued unmet need for evidence-based treatment strategies in HFpEF.

194 s, an increasing body of literature supports evidence-based treatment strategies.

195 implementing equitable access to established evidence-based treatments, substantial gaps remain in ou

196 urative treatments for ADHD do not exist but evidence-based treatments substantially reduce symptoms

197 release, and sooner, than those treated with evidence-based treatments such as methadone, suggesting

198 release, and sooner, than those treated with evidence-based treatments such as methadone, suggesting

199 disorder, clinicians should offer or arrange evidence-based treatment, such as medication-assisted tr

200 nxious individuals do not respond to current evidence-based treatment, suggesting a critical need for

201 okers to attempt to quit and connect them to evidence-based treatment that includes pharmacotherapy a

202 Evidence-based treatments that achieve optimal energy in

203 eatment effectiveness to provide support for evidence-based treatments that can be generalized to the

204 Despite increased experience and evidence-based treatments, the risk of death for patient

205 however, despite the availability of several evidence-based treatments, there is a need for more effi

206 Despite effective, evidence-based treatments, there is significant individu

207 ponding management and shed light on current evidence-based treatments through a 'new' algorithmic ap

208 on is an opportunity to initiate or continue evidence-based treatment to reduce risk in individuals w

209 multicenter registries are needed to provide evidence-based treatments to improve in-hospital outcome

210 Albuminuria testing is crucial for guiding evidence-based treatments to mitigate chronic kidney dis

211 ith adverse prognosis and directs the use of evidence-based treatments to prevent sudden cardiac deat

212 Concurrently, evidence-based treatments to promote smoking cessation a

213 Evidence-based treatment trials for adolescents with ano

214 Evidenced-based treatment trials for adolescents with bu

215 e-renin) and the association of testing with evidence-based treatment using a mineralocorticoid recep

216 settings, accessibility and acceptability of evidence-based treatments vary, and patients may seek a

217 In China, evidence-based treatments were provided less often in 20

218 cause the intervention facilitates access to evidence-based treatment, which typically is less availa

219 tion from exploratory trials to established, evidence-based treatments while avoiding pitfalls that c

220 Head-to-head comparisons with other evidence-based treatments will better inform the potenti

221 rare and was associated with higher rates of evidence-based treatment with MRAs and better longitudin

222 , presenting opportunities for initiation of evidence-based treatments with major potential to improv